Industry still facing Problems with Root Cause Investigations
Recommendation

10/11 February 2026
Risk analysis, preventive measures and incident management
Deviations and CAPA are still important issues during inspections. Inspectors' summaries of their observations show that things do not always work as they should. This also applies to root cause investigations. A look at the FDA's so-called 483s is also interesting here. The observations made by the inspector during an inspection are listed on the FDA Form 483. What many people do not know is that FDA summarises results from the 483s in tables and publishes them in their overview entitled "Inspection Observations".
According to the current file, 349 corresponding forms were issued in the area of "Drugs" in fiscal year 2020. With 79 observations, violations of section 21 CFR 211.192 ("Investigations of discrepancies, failures") are in second place. Primarily, this concerns problems and failures in the review of unexplained deviations and specifications that have not been met. The "Written record of investigation" required in the same paragraph was objected to 28 times. Here, written records of investigations do not always include conclusions and follow-up, or are not even present.
Related GMP News
04.02.2026When Training Falls Short: FDA Findings on GMP Training Deficiencies in 2025
27.01.2026New Ph. Eur. Publication Schedule
21.01.2026EU Pharma Package: EMA with single Point of Information
14.01.2026European QP Association Developments September through December 2025
14.01.2026Could a change of ownership be relevant to GMP?
07.01.2026Is QP Certification required when Products do not enter EU Territory?


